An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Stopped early · Phase 2

Conditions studied: Seizures

In brief

The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.

Key facts

Study ID

NCT04686786

Run by

AbbVie

People needed

105

Starts

2020-12-08

Expected to finish

2024-12-05

Last updated by the study team

2025-12-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who completed treatment in Trial CVL-865-SZ-001 (NCT04244175)
• A female participant of childbearing potential who is sexually active with a nonsterilized male partner must agree to use a highly effective method of contraception from signing of informed consent through 30 days post last dose
• A male participant with a pregnant or a nonpregnant partner of childbearing potential must agree to use a condom during treatment and until the end of relevant systemic exposure in the male participant for 94 days following the last dose with the investigational medicinal product (IMP)
• Participants who are capable of giving signed informed consent
• Participants who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures

You may not qualify if…

• Participants who, in the opinion of the investigator, medical monitor, or sponsor, should not participate in the trial
• Participants who, in the judgment of the investigator, experienced poor tolerability to the IMP during the double-blind trial or whose safety assessments resulted in new concerns that would suggest that the participant may not be appropriate for 57 weeks of treatment with CVL-865 in an extension trial
• Participants who experienced status epilepticus during Trial CVL-865-SZ-001
• Participants who have demonstrated substantial noncompliance to trial procedures in Trial CVL-865-SZ-001, based on the investigator's judgment, would not be eligible for this trial
• Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent), or participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior), or participants who, in the opinion of the investigator, present a serious risk of suicide
• Participants with any of the following abnormalities in clinical laboratory tests at Visit 1, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary (Females: Hemoglobin <11 gram per deciliter (g/dL); Males: hemoglobin <12 g/dL; White blood cell (WBC) count <3.0 x 10 power 9 per liter (10\^9/L); Neutrophil count <2.0 x 10\^9/L; Platelet count <150 × 10\^9/L)
• Participants who would be likely to require the use of prohibited concomitant medications during the trial
• Female participants who have a positive pregnancy test result

Where it is running

• New Haven, Connecticut — New Haven, Connecticut, United States
• Gulf Breeze, Florida — Gulf Breeze, Florida, United States
• Jacksonville, Florida — Jacksonville, Florida, United States
• Miami Lakes, Florida — Miami Lakes, Florida, United States
• Orlando, Florida — Orlando, Florida, United States
• Port Charlotte, Florida — Port Charlotte, Florida, United States
• Tampa, Florida — Tampa, Florida, United States
• Honolulu, Hawaii — Honolulu, Hawaii, United States
• Lexington, Kentucky — Lexington, Kentucky, United States
• Scarborough, Maine — Scarborough, Maine, United States
• Baltimore, Maryland — Baltimore, Maryland, United States
• Bethesda, Maryland — Bethesda, Maryland, United States
• Boston, Massachusetts — Boston, Massachusetts, United States
• Chesterfield, Missouri — Chesterfield, Missouri, United States
• Saint Louis, Missouri — St Louis, Missouri, United States
• Hackensack, New Jersey — Hackensack, New Jersey, United States
• New York — New York, New York, United States
• Rochester, New York — Rochester, New York, United States
• Toledo, Ohio — Toledo, Ohio, United States
• Oklahoma City, Oklahoma — Oklahoma City, Oklahoma, United States
• Philadelphia, Pennsylvania — Philadelphia, Pennsylvania, United States
• Philadelphia, Pennsylvania — Philadelphia, Pennsylvania, United States
• Charleston, South Carolina — Charleston, South Carolina, United States
• Nashville, Tennessee — Nashville, Tennessee, United States
• Little Rock, Arkansas — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.